Director Haya Taitel receives 20,790 Entera Bio (ENTX) shares as fees

Rhea-AI Filing Summary

Taitel Haya reported acquisition or exercise transactions in this Form 4 filing.

Entera Bio Ltd. reported that director Haya Taitel received a board-approved grant of 20,790 ordinary shares on August 7, 2026. The shares were awarded in lieu of cash director fees for the first and second quarters of 2026, after the company filed a Form S-8 registering them. Following this compensation grant, Taitel directly holds 119,269 ordinary shares; the grant carried a reported price of $0.00 per share.

Insider Trade Summary

Net Buyer: 20,790 shares

Net Buy 1 txn

Insider Taitel Haya

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares, par value NIS 0.0000769 per share F1	20,790	$0.00	$0.00

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 119,269 shares (Direct)

Footnotes (1)

1. F1. The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

Key Figures

Shares granted: 20,790 ordinary shares Holdings after transaction: 119,269 ordinary shares Reported grant price: $0.00 per share +3 more

6 metrics

Shares granted 20,790 ordinary shares Grant to director Haya Taitel in lieu of cash fees for Q1 and Q2 2026

Holdings after transaction 119,269 ordinary shares Total direct holdings of director Haya Taitel following the August 7, 2026 grant

Reported grant price $0.00 per share Per-share price reported for the 20,790-share compensation grant

Par value NIS 0.0000769 per share Par value of Entera Bio Ltd. ordinary shares granted to the director

Form S-8 filing date August 7, 2026 Date the company filed Form S-8 registering the compensation shares

Board approval date August 5, 2026 Date the board approved the share grant, subject to S-8 registration

Key Terms

Grant, award, or other acquisition, Registration Statement on Form S-8, in lieu of the cash fees

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Registration Statement on Form S-8 regulatory

"subject to the filing by the Company of a Registration Statement on Form S-8"

A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.

in lieu of the cash fees financial

"awarded these shares to the Reporting Person in lieu of the cash fees"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 04:22 PM Accepted by SEC EDGAR 08/07/2026 - 04:22 PM Learn about SEC filing dates

FAQ

What insider transaction did Entera Bio (ENTX) disclose in this Form 4?

Entera Bio disclosed that director Haya Taitel received a grant of 20,790 ordinary shares as stock compensation. The award was approved by the board and issued after a Form S-8 registered the shares, increasing her direct holdings to 119,269 shares.

How many Entera Bio (ENTX) shares did director Haya Taitel receive?

Director Haya Taitel received 20,790 ordinary shares of Entera Bio Ltd. The shares were granted as compensation in stock rather than cash fees for her board service in the first and second quarters of 2026, with a reported per-share price of $0.00.

Was the Entera Bio (ENTX) share grant to Haya Taitel paid in cash?

No. The 20,790-share grant to director Haya Taitel was awarded in lieu of cash fees for her services as a director for the first and second quarters of 2026, meaning she received stock instead of the cash compensation otherwise payable.

When were Haya Taitel’s Entera Bio (ENTX) shares approved and registered?

The board approved the share grant on August 5, 2026, subject to registration. Entera Bio then filed a Registration Statement on Form S-8 covering these shares, which occurred on August 7, 2026, the same date reported for the grant transaction.

How many Entera Bio (ENTX) shares does Haya Taitel hold after this Form 4 transaction?

After receiving the 20,790-share grant, director Haya Taitel directly holds a total of 119,269 ordinary shares of Entera Bio Ltd. This figure reflects her position immediately following the reported stock compensation transaction on August 7, 2026.

What type of security was granted to Haya Taitel by Entera Bio (ENTX)?

The compensation grant to Haya Taitel consisted of ordinary shares of Entera Bio Ltd., each with a par value of NIS 0.0000769 per share. These were issued as non-derivative equity, not options or other derivative securities, according to the Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taitel Haya

(Last) (First) (Middle)

KIRYAT HADASSAH, MINRAV BUILDING

5TH FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	08/07/2026		A(1)		20,790	A	$0	119,269	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)